Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$NAHD Video Profile: Join Olenox Corp ($NAHD) as CEO Michael McLaren discusses Olenox Corp's groundbreaking tech that's reshaping the energy sector. Find out how they're transforming neglected oil and gas sites into sustainable assets, all while prioritizing both the environment and community well-being.
$BLIS News: NAPC Defense, Inc. (OTCPK: BLIS) updates Progress with Saudi Arabia regarding Future Plans and CornerShot Demonstrations
LARGO, Fla., Aug. 13, 2024 (GLOBE NEWSWIRE) -- NAPC Defense, Inc., (OTCPK: BLIS) (“NAPC” or “the Company”) announces that its representatives have returned from their meetings with interested parties in Europe and Saudi Arabia, concerning its CornerShot products, various munitions, and other military hardware.
The NAPC representatives made progress with their Saudi Arabian counterparts and the potential for proposed contracts remains promising. NAPC received a $253,000 Purchase Order to support technical activity and expertise for CornerShot, drones, and other munitions. This support requires sending in country personnel to assist the Saudi Ministry of Defense (“MOD”) with technical questions and training.
https://ml.globenewswire.com/Resource/Download/bfacedcc-0a5d-4443-9534-c3db982e152a/napc-saudi.jpeg
Pictured from left to right are John Spence, NAPC CFO, Stephen Gurba, NAPC President, Eng. Abdullah Mohamed Al Bassami, and Eng. Abdul Qader AI Bassami; in front of Saudi Prince’s Palace, during their recent meetings.
NAPC representatives are expected to return to Saudi Arabia by the end of August to support a seven-day demo event and to advance its existing large intended order for CornerShot. Due to unexpected active military activities on the Saudi Arabian border during NAPC’s recent trip, civilians in general, including the Company’s representatives, were restricted access to conduct the necessary CornerShot demonstrations with MOD leaders and soldiers.
John Spence, NAPC Defense’s CFO and weapons specialist, stated, “Our visit with leaders in Saudi Arabia advanced our relationship in so many positive ways. We appreciated the hospitality and eagerness to conduct business with our team, opening the door to many new potential contracts. We also fully expect NAPC Defense to finalize agreements for large orders of CornerShot following live demonstrations.”
About NAPC Defense, Inc.
NAPC Defense, Inc. https://www.napcdefense.com/ is an armament sales and production company, fully licensed in the United States, with exclusive rights to produce and sell CornerShot USA weapons systems in the U.S. and Saudi Arabia, in addition to brokering arms and munitions throughout the world all with U.S. State Department approval. Additional smaller weapons platforms, a series of ballistics protection technologies and related products are in development or being finalized for sale.
FORWARD LOOKING STATEMENTS:
This press release and the statements of representatives of NAPC (the “Company”) related thereto contain, or may contain, among other things, “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact included herein are “forward-looking statements,” including any other statements of non-historical information.
These forward-looking statements are subject to significant known and unknown risks and uncertainties and are often identified by the use of forward-looking terminology such as “guidance,” “projects,” “may,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “ultimately” or similar expressions. All forward-looking statements involve material assumptions, risks and uncertainties, and the expectations contained in such statements may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results (including, without limitation, NAPC's ability to advance its business, generate revenue and profit and operate as a public company) could differ materially from those stated or anticipated in these forward-looking statements as a result of a variety of factors, including factors and risks discussed in the periodic reports that the Company files with the SEC. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. The Company undertakes no duty to update these forward-looking statements except as required by law.
COMPANY CONTACT:
Kenny West, CEO (754) 242-6272 Ext.713
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/bfacedcc-0a5d-4443-9534-c3db982e152a
https://www.globenewswire.com/newsroom/ti?nf=OTIwMzgwNCM2NDIwOTEyIzIyNjE1MDY=
https://ml.globenewswire.com/media/NTVkMTJlYTctY2MxNS00NjJjLWE2OWMtY2MyZTk0Y2QyYzNjLTEyNzMwNTY=/tiny/Treasure-Shipwreck-Recovery-In.png
Pictured from left to right are John Spence, NAPC CFO, Stephen Gurba, NAPC President, Eng. Abdullah Mohamed Al Bassami, and Eng. Abdul Qader AI Bassami; in front of Saudi Prince’s Palace, during their recent meetings.
Pictured from left to right are John Spence, NAPC CFO, Stephen Gurba, NAPC President, Eng. Abdullah Mohamed Al Bassami, and Eng. Abdul Qader AI Bassami; in front of Saudi Prince’s Palace, during their recent meetings.
Source: NAPC Defense, Inc.
© 2024 GlobeNewswire, Inc.
Thanks!!!!
I will take a look!!!
Hi, take a look at News on $BLIS today NAPC Defense, Inc. (OTCPK: BLIS) begins Highly Anticipated Visits with Key European Contacts, and to Saudi Arabia for CornerShot Demonstrations
LARGO, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- NAPC Defense, Inc. (OTCPK: BLIS) (“NAPC”) announces that its representatives began its European and Saudi Arabian corporate trip. For the past two weeks, management met with defense contracting partners in Germany and other countries for strategic supply of needed defense items for Allied Countries.
The NAPC team is now in Saudi Arabia, upon invitation from the Saudi Government and related Ministries, and will perform numerous live-fire demonstrations of CornerShot firearm tactical devices. Additionally, NAPC Defense will be representing other arms and munitions technology for potential orders, as well as other related business as requested by parties from Saudi Arabia.
As previously announced, NAPC received a signed and stamped LOI from Saudi Arabia for an initial order of 37,000 units of the CornerShot, valued at (U.S.) $370 million. Following its visit and demonstrations, NAPC anticipates a new Definitive Order Agreement.
The CornerShot technology licensed from Silver Shadow of Israel will be manufactured by NAPC Defense in the United States near its Largo, Florida headquarters. All necessary production equipment has been ordered and paid for so that large scale production of the CornerShot can begin in the near-term. NAPC Defense has an exclusive license to produce and sell CornerShot for Saudi Arabia and The United States.
Recently, NAPC Defense displayed and presented the CornerShot at police and tactical unit conferences in Florida and New Jersey, with significant order interest. NAPC has also demonstrated CornerShot to several law enforcement and military units at its Largo, Florida location, utilizing its indoor smokeless demonstration range and real range use.
As previously disclosed, NAPC Defense is licensed and approved to broker munitions and military hardware already produced and in inventory at various locations worldwide. NAPC anticipates orders for different munitions and military hardware items that are of need to Allied and NATO forces for the Ukrainian conflict and the Middle East. The inventory of these items, if sold at currently offered fair value, totals over (U.S.) $2.5 billion. NAPC would realize appreciable 10-20% fees for such brokering transactions.
$AVRW Avenir Wellness Solutions™ ($AVRW) Skin Care Products are Sold at Walmart $WMT , Target $TGT , CVS Health $CVS , and Amazon $AMZN Retail Outlets. Accelerating Sales for Superior Anti-Aging Skin Care Line with Direct Endorsement of Nicole Kidman https://www.einpresswire.com/article/660866879/accelerating-sales-for-superior-anti-aging-skin-care-line-with-direct-endorsement-of-nicole-kidman-stock-symbol-avrw
$AVRW News: Avenir Wellness Solutions Reports Fourth Quarter 2023 Results
New Initiatives Showing Encouraging Results
SHERMAN OAKS, CA / ACCESSWIRE / May 17, 2024 / Avenir Wellness Solutions, Inc. (OTCQB:AVRW) ("Avenir" or the "Company"), a proprietary broad platform technology and wellness company, today announced results for the fourth fiscal quarter ended December 30, 2023.
Key financial highlights for the fourth quarter included the following:
Net revenue in the fourth quarter of 2023 increased to $1.1 million from the same period in 2022 by $0.2 million, or 11.7%, and also increased sequentially from Q3 2023 by $43 thousand, or 4.4%. Overall growth was lower than expected due to the continued delay in receiving the expected remainder of the asset sale proceeds to be used for advertising and marketing to drive sales. The quarter did, however, benefit from a new relationship with leading online and beauty subscription box retailer, FabFitFun.
Gross margin increased 407 basis points year over year in the fourth quarter of 2023 due to improved working capital management offset in part by a higher proportion of sales coming from our wholesale channel of distribution with its lower margins than our higher-margin direct-to-consumer sales channel.
Gross margin for the third quarter of 2023 decreased sequentially from the second quarter of 2023 by 26 basis points due to a shift in sales channel mix with a higher proportion of wholesale sales to Amazon and FabFitFun which resulted in shipments of approximately $0.3 million.
Cost containment initiatives led to a favorable impact on SG&A expenses (excluding non-cash charges) for the fourth quarter with a decrease of $357 thousand in 2023 compared to 2022 driven by decreased spend on advertising and promotion of $325 thousand lower overhead by $32 thousand.
Net operating loss from continuing operations (excluding non-cash charges) improved by $0.9 million in 2023.
"Our products continue to maintain sales levels which is encouraging given that we have been unable to fully execute on our marketing initiatives pending receipt of the balance of the proceeds from the July 2022 asset sale. As mentioned in our third quarter earnings announcement, the proceeds from the July 2022 asset sale allow us to invest in the future of the Company, but the delay in receiving the balance of the proceeds continued to have an impact on our operating performance. We expect accelerating sales will reaffirm the improving overall trajectory of the business. Further, our margin expansion initiatives continue to deliver results with improvement from third quarter, and we continue our overall cost containment initiatives to further reduce SG&A expenses and to maximize operating leverage.
Fine tuning our Search Engine Optimization (SEO), bringing our media buying in house and achieving successful monthly campaigns like theSkimm continue to deliver for us as we execute on our strategy to build our brands," said Nancy Duitch, Avenir CEO.
Operational Highlights
Other operational highlights during the fourth quarter of 2023 included:
Our newly formulated Seratopical Revolution Cracked Heel Souffle was selected for inclusion in FatFitFun's Summer 2024 subscription box selling out an astonishing 80,000 units in under 43 minutes. Click link to view Instagram videos on our Cracked Heel Souffle.
Our DNA Complex hero product continues to perform as our subscription based grows.
Wholesale sales led by Amazon continue to grow with all the positive product reviews.
We began development of our new TikTok shop to capitalize on the evolving digital ecommerce landscape which launched in the second quarter of 2024.
For further details, please visit our website to review our most recent Form 10-K filed on May 17, 2024 at: http://www.avenirwellness.com/sec-filings/
About Avenir Wellness Solutions, Inc.
Avenir Wellness Solutions, Inc. (OTCQB:AVRW) is a broad platform technology company that develops proprietary wellness, nutraceutical, and topical delivery systems which are integrated into our wellness and beauty products and sold directly to the consumer. The technology, which is based on (15) fifteen current patents, offers a number of unique immediate- and controlled-release delivery vehicles designed to improve product efficacy, safety, and consumer experience for a wide range of active ingredients. The Company will continue down the path of creating new technologies that is part of its incubator strategy in order to monetize its intellectual property as well as expand our product lines utilizing the technology. As a vertically integrated platform company, Avenir looks to partner or license its IP technology with wellness companies worldwide. For more information visit: http://www.avenirwellness.com.
About The Sera Labs, Inc.
Sera Labs, a wholly owned subsidiary of Avenir, is a trusted leader in the health, wellness, and beauty sectors of innovative products with cutting-edge technology. Sera Labs creates high-quality products that use science-backed, proprietary formulations. More than 25 products are sold under the brand names Seratopical™, Seratopical Revolution™, SeraLabs™, and Nutri-Strips™. Sera Labs sells its products at affordable prices, making them easily accessible on a global scale. Strategically positioned in the growth market categories of beauty, health and wellness, Sera Labs products are sold direct-to-consumer (DTC) via online website orders, including a subscribe and save option, and also sold online and in-store at major national drug, grocery chains, convenience stores, and mass retailers and on Amazon.com. For more information visit: http://www.seralabshealth.com and follow Sera Labs on Facebook, Instagram and TikTok at @seratopical as well as on X (Twitter) at @sera_labs.
Forward Looking Statement
This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which statements are subject to considerable risks and uncertainties. Forward-looking statements include all statements other than statements of historical fact contained in this press release, including statements regarding the future growth and success of our organization. We have attempted to identify forward-looking statements by using words such as "anticipate," "believe," "could," "estimate," "expected," "intend," "may," "plan," "predict," "project," "should," "will," or "would," and similar expressions or the negative of these expressions.
Forward-looking statements represent our management's current expectations and predictions about trends affecting our business and industry and are based on information available as of the time such statements are made. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy or completeness. Forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements predicted, assumed or implied by the forward-looking statements. Some of the risks and uncertainties that may cause our actual results to materially differ from those expressed or implied by these forward-looking statements are described in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as well as in our Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Except as required by applicable law, we expressly disclaim any intent or obligation to update any forward-looking statements, or to update the reasons actual results could differ materially from those expressed or implied by these forward-looking statements, whether to conform such statements to actual results or changes in our expectations, or as a result of the availability of new information.
CONTACTS:
Investor Relations
Hanover International Inc.
T: (760) 564-7400
E: investor@avenirwellness.com
$CATV: Category V Biotech, Inc. Announces Letter of Intent to Acquire Genetic Networks, Expanding into Biotechnology Sector
MIAMI, May 15, 2024 /PRNewswire/ -- 4Cable TV International, Inc. soon to be known as Category V Biotech, Inc. (OTC: CATV) announced today the execution of a Letter of Intent (LOI) to acquire Genetic Networks, LLC (https://geneticnetworks.com/), a leader in applied molecular biology and drug development. Effective May 15, 2024, the LOI signifies Category V Biotech's acquisition of 100% equity interests in Genetic Networks, marking the company's entry into the biotechnology sector of the Cannabis industry and solidifying its position as a fully integrated global leader in this space.
Genetic Networks brings a proprietary platform known as GeneScape™, which facilitates the rapid and unbiased discovery of optimal drug compounds through whole-genome analysis. By integrating functional assays of drug activity and human gene variants, GeneScape™ can identify the most promising targets and compounds for specific diseases, expediting development timelines and reducing costs. This acquisition enables Category V Biotech to expand into the biotech aspect of the Cannabis industry, leveraging Genetic Networks' expertise in accelerating compound discovery and development for pre-clinical and clinical testing.
"We are excited to welcome Genetic Networks into the Category V Biotech family," stated Michael Feldenkrais, CEO of Category V Biotech. "Their state-of-the-art platform and extensive knowledge will be instrumental as we strive to unlock the full potential of Cannabis-based therapeutics. Together, we anticipate bringing novel treatments to patients faster than ever before as regulated FDA products under the new regulatory environment of the United States."
Under the agreement's terms, Category V Biotech will acquire 100% of Genetic Networks. The transaction is expected to conclude in the second quarter of 2024, pending customary closing conditions.
Dr. Gennaro D'Urso, co-founder of Genetic Networks, echoed this enthusiasm, stating, "Category V Biotech shares our dedication to leveraging genetics to revolutionize drug development. By joining forces, we envisage broadening the reach and impact of our platform, ultimately delivering superior medicines to patients in need."
Following the acquisition, Genetic Networks will operate as a wholly owned subsidiary of Category V Biotech, retaining its existing management team and facilities. Category V Biotech plans to leverage Genetic Networks' capabilities across its global Cannabis operations, including cultivation, biotech research, and retail.
This transaction is the culmination of years of discussions, awaiting the right moment for research and development in the United States to create pharmaceutical-grade products using Cannabis. With the recent announcement of the rescheduling of Cannabis from Controlled Substance I to Controlled Substance III, reflecting a change in U.S. policies, the long-awaited strategy can now come to fruition. This shift paves the way for Category V Biotech and Genetic Networks to capitalize on emerging opportunities in the Cannabis industry, driving innovation and advancing therapeutic solutions for patients.
Category V Biotech remains actively engaged in pursuing additional acquisitions in the Cannabis industry as part of its growth strategy, with further transactions expected to be announced in the coming months.
About Genetic Networks, LLC
Genetic Networks, LLC, established in 2015, has been at the forefront of serving three of the top ten bio-pharmaceutical companies with its GeneScape™ technology. GeneScape™ expedites drug asset development through applied molecular biology, offering a multidimensional map of diseases and drugs that integrates genome-wide functional assays of drug activity (H-Tech) and human genes and gene variants (Y-Tech) using proprietary analytics. Genetic Networks' GeneScape™ platform accelerates the discovery and development of optimal candidate compounds for pre-clinical and clinical testing, identifying the optimal intersection between targets and compounds in specific disease spaces through whole-genome genetic perturbation and analysis.
About Category V Biotech, LLC, Inc.
Category V Biotech, LLC, Inc. (OTC: CATV) aims to establish and operate a fully integrated global Cannabis company, encompassing biotech research, cultivation, manufacturing, and retail. Through strategic acquisitions and organic growth, the company strives to emerge as the world's leading provider of pharmaceutical Cannabis- based products and therapies.
Cautionary Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements regarding Category V Biotech, LLC's business, which are not historical facts but are based on the company's current beliefs, expectations, and assumptions about its future business, plans, strategies, projections, anticipated events, and trends. Such forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are beyond the company's control. Actual results and financial conditions may differ materially from those indicated in the forward- looking statements due to various factors. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, made from time to time, except as required by law.
SOURCE: 4Cable TV International, Inc a/k/a Category V Biotech, LLC, Inc. (OTC: CATV)
Contact: info@4cabletvint.com, +1 3055289614
Cision View original content:https://www.prnewswire.com/news-releases/category-v-biotech-inc-announces-letter-of-intent-to-acquire-genetic-networks-expanding-into-biotechnology-sector-302146392.html
SOURCE 4Cable TV International, Inc.
$RENB News: Renovaro, Inc. Announces $10 million in Equity Committed
LOS ANGELES, June 14, 2024 (GLOBE NEWSWIRE) -- Renovaro, Inc. (NASDAQ: RENB) (the “Company”) announces that it has $10 million in additional equity committed at a price per share of $1.4726 and 10 percent warrant coverage.
“We appreciate confidence in the Company demonstrated by the investors,” said the Hon. Mark Dybul, MD, CEO. “We believe this is only the beginning. We are hopeful to be able to secure additional financing such as, but not limited to, long-term loans, grants and subsidies from various US and European institutions for which the Company is eligible – potentially worth tens of millions of dollars.”
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline and platform. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For media inquiries, please contact: karen@renovarocube.com
Source: Renovaro Inc.
$NRXP News: NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2024 Financial Results and Provides Business Update
2024 Catalysts: Positive Clinical Data, Two Planned NDAs, Company Launch of Hope Therapeutics; FDA QIDP award in cUTI and New Schizophrenia Opportunity
Executed Term Sheet from an institutional investor for an initial $7.5 million note, subject to common closing requirements, primarily to replace current debt, clearing the path to a Hope Therapeutics share distribution, with provision for funding up to $30 million to fund pipeline opportunities
Positive data from a Phase 2b/3 trial of NRX-101 in Treatment Resistant Bipolar Depression (TRBD); trial demonstrated depression efficacy comparable to standard of care and significant reduction of akathisia (P=0.025). Akathisia is a potentially lethal side effect of all serotonin-targeted antidepressants and is associated with suicide. The study additionally demonstrated a 30% advantage in sustained remission from suicidality that was not statistically-significant at this sample size
Above findings of reduced suicidality mirror the results of the Company's prior STABIL-B trial in acutely suicidal patients and also mirror the results of an independent published trial
Company plans to file a New Drug Application (NDA) for Accelerated Approval under Breakthrough Therapy and Priority Review of NRX-101 in treatment of bipolar depression in people at risk of akathisia, based on the Phase 2b/3 and STABIL-B data
Company has developed patentable pH neutral formulation for ketamine that will be suitable for both intravenous and subcutaneous administration. Ketamine efficacy data are in hand from 4 clinical trials. Three manufacturing lots are now initiated (required for NDA) and Company plans to initiate the NDA by July
HOPE Therapeutics (which focuses on care delivery, not drug development) has partnered with representatives of ketamine clinic providers nationwide to construct a care platform that will include ketamine, operational support, and digital therapeutic extensions. In advance of FDA approval, HOPE is actively in the sales process to supply ketamine under 503b pharmacy licensure to meet the national ketamine shortage declared by FDA. HOPE is planned to be spun out as a separate company to be owned by NRx, current NRx shareholders, and new investors; Term Sheets received from prospective anchor investors for $60 million of new investment, once publicly listed
Data expected shortly in 200-person DOD-funded trial of D-cycloserine (DCS), the key component of NRX-101, to treat chronic pain, conducted by Northwestern University. Statistical analysis plan and data unlock have been approved by Northwestern IRB
NRX-101 in the treatment of Complicated Urinary Tract Infection (cUTI) granted Qualified Infectious Disease Product (QIDP), Fast Track, and Priority Review designations. Company has now demonstrated that NRX-101 does not damage the microbiome of the gut, in contrast to all other advanced antibiotics and is less likely to cause C. Difficile infection (a potentially lethal side effect of antibiotic treatment). NRx is reviewing partnership options
Executed Memorandum of Understanding with Fondation FundaMental for rights to develop potential disease modifying drug for Schizophrenia. If successful, this would represent the first drug to reverse the underlying disease mechanism of schizophrenia, rather than simply treating symptoms.
Management to host a conference call, May 14, 2024, at 4:30 PM ET
RADNOR, Pa., May 14, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced its financial results for the quarter ended March 31, 2024, and provided a business update.
"NRx has had an incredibly productive start to 2024, delivering positive data from our phase 2b/3 trial of NRX-101 in suicidal bipolar depression, where we demonstrated what could potentially be a best-in-class medication for people with bipolar disorder. To our knowledge, this is the first successful clinical trial ever conducted with an oral antidepressant in patients with suicidal depression who have been excluded from all antidepressant trials in the past. We plan to file a New Drug Application based on these and previous findings. In addition, we have advanced Hope Therapeutics and IV Ketamine, HTX-100, towards the filing of an NDA this summer, and continue to prepare to capitalize on the opportunity for NRX-101 in chronic pain and complicated UTI," said Stephen Willard, J.D., Chief Executive Officer and Director of NRx Pharmaceuticals. "Together these opportunities constitute treatments that can meet considerable unmet medical need in up to 75,000,000 patients across the country. Obviously, this would build incredible value for our shareholders. We are dedicated to bringing hope to life and I thank our team and shareholders for their ongoing hard work and support. Lastly, we are pleased to have signed a term-sheet to replace the toxic debt on our balance sheet with a new commitment from a solid, institutional investor."
First Quarter Clinical, Regulatory and Corporate Highlights
Development of NRX-101 for Suicidal Treatment-Resistant Suicidal Bipolar Depression
The Company announced final data from the recently completed phase 2b/3 trial of NRX-101 in suicidal bipolar depression, with a significantly improved safety profile as demonstrated by a statistically significant reduction in akathisia, an adverse event considered by many experts to be a precursor to suicide. Given the vital need for safer medications in this at-risk population, we plan to submit an NDA to the US FDA for treatment of bipolar depression patients at risk of akathisia, based on these data as well as additional data from our STABIL-B1 trial.
Efficacy Measures: Repeated Measures Mixed Model LS Mean Differences
Through Day 28
Through Day 42
LOCF No
LOCF yes
LOCF No
LOCF Yes
MADRS Depression Score
LS Mean ?
p-value
LS Mean ?
p-value
LS Mean ?
p-value
LS Mean ?
p-value
-4.0
0.09
-7.7
0.03
-3.7
0.04
-7.7
0.04
Suicidality Rating Scale C-SSRS
LS Mean ?
p-value
LS Mean ?
p-value
LS Mean ?
p-value
LS Mean ?
p-value
-0.5
NS
-1.3
0.04
-0.6
NS
-1.5
0.02
Clinical Global Impression CGI-SS
LS Mean ?
p-value
LS Mean ?
p-value
LS Mean ?
p-value
LS Mean ?
p-value
-0.4
NS
-2.9
0.05
-0.6
NS
-2.9
0.02
During 2024, the Company began working in unison with Alvogen and Lotus Pharmaceuticals to plan the final development and commercialization of NRX-101. These partners recently advanced $5 million of the first milestone to the Company. Final licensing of the product, expected in Q2 2024, will yield a total of $9 million in milestone payments together with assumption of future development costs by our partners. The partnership provides for potential milestones of $329 million and a royalty reaching 15% on Net Sales.
NRX-101 for Treatment of Chronic Pain:
In 2023, the Company licensed US Patent 8,653,120 for the use of DCS in chronic pain and filed a now-accepted Investigational New Drug (IND) application with the FDA to initiate commercial drug development of NRX-101 in chronic pain. Data lock has now been achieved in a 200-person randomized prospective trial funded by the US DOD (NCT 03535688) in which patients with chronic pain were randomly assigned to DCS 400mg/day vs. placebo. Should these results support efficacy of DCS in the treatment of chronic low back pain, they are expected to provide a Breakthrough Therapy path towards treatment of chronic pain with DCS and DCS-containing medicines.
Incorporation of HOPE Therapeutics and progress towards an NDA for HTX-100 (IV ketamine) in the treatment of suicidal depression
Intravenous ketamine has now become a standard of care for acute treatment of suicidal depression, in the absence of an FDA-labeled product. Intranasal Esketamine is approved by the FDA (SPRAVATO®), but has not demonstrated a benefit on suicidality and is not approved for use in patients with bipolar depression. Attempts to use intranasal racemic ketamine for suicidal depression have failed.
The Company has formed data-sharing partnerships to license clinical trial data from a French Government-funded trial and two NIH-funded trials all of which demonstrate efficacy of racemic Intravenous ketamine against depression and two of which demonstrate statistically significant benefit vs suicidality. The Company's role is to reformat these data into the required presentation required for review by the FDA.
In contrast to nasal ketamine, Intravenous racemic ketamine demonstrates dramatic and immediate reduction of suicidality in patients with both Major Depressive Disorder and Bipolar Depression. Grunebaum and colleagues demonstrated a rapid and statistically significant reduction in Suicidal Ideation (SSI) at day 1 (p=0.0003) and in depression (P=0.0234), as measured by the Profile of Mood States (POMS) among patients randomized to IV Ketamine compared to those randomized to midazolam. This trial was published in the American Journal of Psychiatry Grunebaum, et.al.2. Abbar and colleagues similarly published 84% remission from suicidality on the Columbia Suicide Severity Rating Scale (C-SSRS) in patients treated with ketamine, vs. 28% in those treated with placebo (P<.0001). This trial was published in the British Medical Journal3. Data are expected to be transmitted to FDA by July 2024.
In November 2023, the Company initiated manufacture of ketamine together with Nephron Pharmaceuticals, Inc. (West Columbia, SC) to develop a single patient presentation of ketamine. Nine months of real-time stability is ongoing, the minimum stability time required for a New Drug Application.
A long-term challenge with ketamine is that the current formulation (KETALAR®) is highly acidic. While it is suitable for intravenous use, it cannot be administered subcutaneously. In March 2024 the Company demonstrated the formulation of a pH neutral patentable form of IV ketamine that it anticipates will have widespread applicability both in treatment of depression and chronic pain.
Treatment of Urinary Tract Infection (UTI) and Urosepsis:
Although treatment of UTI is quite different from use of NRX-101 to treat Central Nervous System disorders, D-cycloserine was originally developed as an antibiotic because of its role in disrupting the cell wall of certain pathogens. During Q3 2023, NRx tested NRX-101 and its components against resistant pathogens that appear on the Congressionally mandated Qualified Infectious Disease Product (QIDP) list and proved in vitro effectiveness against antibiotic-resistant E. coli, Pseudomonas, and Acinetobacter. Accordingly, NRx was granted QIDP designation, Fast Track Designation, and Priority Review by the US FDA in January 2024.
In recent years, increased antibiotic resistance to common pathogens that cause urinary tract infections and urosepsis (i.e., sepsis originating in the urinary tract) has resulted in a marked increase in cUTI, hospitalization, and death from urosepsis. The US Center for Disease Control and Prevention reports that more than 1.7 million Americans contract sepsis each year, of whom at least 350,000 die during their hospitalization or are discharged to hospice (CDC Sepsis Ref.)4. There are approximately 3 million patients per year who contract cUTI in the US annually (Lodise, et. al.)5. Additionally, should NRX-101 succeed in clinical trials, the Company will consider developing a follow-on product that is anticipated to achieve another 20 years of patent exclusivity.
A key challenge in the treatment of cUTI is the tendency of advanced antibiotics to cause C. Difficile infection, which is fatal in 10% of those who contract it over the age of 65 and results in prolonged hospitalization in many more. The Company recently announced data demonstrating that NRX-101 does not compromise the intestinal microbiome, unlike common antibiotics including Clindamycin and Ciprofloxacin. Should these findings be documented in human patients, NRX-101 would represent the only treatment for cUTI that does not cause C. Difficile infection.
In The Company does not anticipate funding this initiative with core NRx assets and is exploring structures for partnership opportunities. Should the Company or its partners succeed in serving 10% of the cUTI market, the Company believes that the revenue from NRX-101 has the potential to hundreds of million annually, based on 3 million cases per year in the US and potential pricing of over $3,500/course of therapy.
Financial Results for the Quarter and Year Ended December 31, 2023
For the three months ended March 31, 2024, NRx Pharmaceuticals reduced net loss from $11.0 million in the first quarter of 2023 to $6.5 million in 2024, representing a 41% improvement year over year. For that same period, Research and Development expenses decreased from $3.7 million in 2023 to $1.7 million in 2024, as clinical trial enrollment concluded. The $2.0 million decrease is related primarily to a decrease of $1.6 million in clinical trial expenses, $0.2 million in regulatory and process development costs, and $0.1 million in stock-based compensation. The Company also recorded a 26% reduction in general and administrative expenses during the quarter, from $5.8 million in 2023 to $4.3 million in 2024. The decrease of $1.5 million is related primarily to a decrease of $1.2 million in insurance expenses, $0.4 million employee expense, and slightly offset by other general and administrative expenses.
As of March 31, 2024, the Company had $1.3 million in cash and cash equivalents, not including the $5.1 million of working capital committed by Alvogen. This included a reduction of corporate indebtedness to Streeterville LLC of $2.2 million. Subsequent to March 31, 2024, we increased working capital by $3.3 million from equity sales. Over the first three months of 2024 the Company improved access to working capital by $8 million in total, representing $2.9 million from equity sales and $5.1 million from the Alvogen milestone advance, while reducing corporate indebtedness by 50%.
NRx continues to implement operational efficiencies to extend cash runway and maintain focus on our path to generating revenue and value for our shareholders.
Please see detailed financials on our Form 10-Q, filed with the SEC and available on our website.
Conference Call and Webcast Details
A live webcast of the conference call will be available on the Company's website at 4:30 p.m. ET today, at https://ir.nrxpharma.com/events. An archive of the webcast will be available on the Company's website for 30 days. Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically 1-800-717-1738 or internationally 1-646-307-1865.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
1
Nierenberg et al. International Journal of Bipolar Disorders (2023) 11:28 https://doi.org/10.1186/s40345-023-00
2
Grunebaum, et. al., Ketamine for Rapid Reduction of Suicidal Thoughts. Am J Psychiatry. 2018 Apr 1: 175(4): 327-335
3
Abbar, et. al. Ketamine for Acute Treatment of Severe Suicidal Ideation, BMJ 2022; 376
4
https://www.cdc.gov/sepsis/what-is-sepsis.html
5
Open Forum Infectious Diseases, Volume 9, Issue 7, July 2022, ofac315, https://doi.org/10.1093/ofid/ofac315
https://c212.net/c/img/favicon.png?sn=CL14310&sd=2024-05-14 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-reports-first-quarter-2024-financial-results-and-provides-business-update-302145361.html
SOURCE NRx Pharmaceuticals, Inc.
$RENB Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy https://finance.yahoo.com/news/renovaro-inc-amsterdam-umc-cancer-132000390.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr
$CCTG: News: CCSC Technology International Holdings Limited Announces Plan for New Supply Chain Management Center in Central Europe
Thu, May 16, 2024, 8:00 AM EDT
In this article: $CCTG -CCSC Technology International Holdings Limited
Hong Kong, May 16, 2024 (GLOBE NEWSWIRE) -- CCSC Technology International Holdings Limited (the “Company” or “CCSC”) (Nasdaq: CCTG), a Hong Kong-based company that engages in the sale, design and manufacturing of interconnect products, including connectors, cables and wire harnesses, today announced that the Company plans to commence construction of a new Europe supply chain management center (the “Center”) located in Municipality of Merosina, Republic of Serbia (“Serbia”), in August 2024. The 50,000-square-meter facility will be CCSC’s first supply chain center project and is scheduled for completion in 2025. Once completed, it will serve as the headquarters of the Company's supply chain operations in Europe.
To further optimize production efficiency and boost synergy, in February 2024, CCSC formed a new subsidiary, CCSC Technology Doo Beograd, in Belgrade, Serbia. This subsidiary will be responsible for the operations of our new Europe supply chain management. The Company plans to adopt modern automation solutions and three-dimensional storage technology to optimize the use of the storage space, and leverage the latest digital technologies to build a smart supply chain management platform at the Center. The facility will serve as a key integrated supply chain transit hub, supporting the Company's operations across Europe.
This project is fully supported by the Merosina government, with a signed memorandum of understanding marking the collaboration between CCSC Technology Doo Beograd and the Municipality of Merosina. The total investment for the Center is estimated at US$6 million.
Mr. Kung Lok Chiu, Chief Executive Officer and Director of the Company, commented, "As part of our on-going strategic plan, we will continue to widen our strategic moat by investing in supply chain infrastructure to further enhance the agility and resiliency of our business. We believe our new Center will better support our business by driving long-term growth. This initiative is also crucial in our endeavors to become a leader in the interconnect products market. We are committed to adopting the most advanced technologies, developing replicable and scalable solutions, and fostering innovative ideas and products."
About CCSC Technology International Holdings Limited
CCSC Technology International Holdings Limited, is a Hong Kong-based company that engages in the sale, design and manufacturing of interconnect products. The Company specializes in customized interconnect products, including connectors, cables and wire harnesses that are used for a range of applications in a diversified set of industries, including industrial, automotive, robotics, medical equipment, computer, network and telecommunication, and consumer products. The Company produces both OEM (“original equipment manufacturer”) and ODM (“original design manufacture”) interconnect products for manufacturing companies that produce end products, as well as electronic manufacturing services (“EMS”) companies that procure and assemble products on behalf of such manufacturing companies. The Company has a diversified global customer base located in more than 25 countries throughout Asia, Europe and the Americas. For more information, please visit the Company’s website: http://ir.ccsc-interconnect.com.
Forward-Looking Statements
Certain statements in this announcement are forward-looking statements, including, but not limited to, the Company's proposed Offering. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “may,” “will,” “could,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “propose,” “potential,” “continue”, or other similar expressions in this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the U.S. Securities and Exchange Commission.
For more information, please contact:
CCSC Technology International Holdings Limited
Investor Relations Department
Email: ir@ccsc-interconnect.com
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com
$AVRW: Avenir Wellness Solutions has never been in a better position to capitalize on the high intrinsic value of our unique and proprietary skin care formulations. With 15 patents under our control, the highly positive reviews Seratopical DNA Complex is receiving, and more new products in development, 2024 is set up to be a growth year for the Company. We look forward to keeping our shareholders informed of our progress, developments and milestones as we move forward.
Sincerely,
Nancy Duitch, CEO
News Link:
https://finance.yahoo.com/news/avenir-wellness-solutions-issues-2024-140000098.html
$EVKRF News: Grid Battery Metals Team Provides Nevada Exploration Update for 2024
Click here for news with images:
https://finance.yahoo.com/news/grid-battery-metals-team-provides-123000945.html
DLOC and for many weeks to come in a massive rum here to silver. You heard it here first. See my dd.
What are we watching this week bud?
$AVRW, with its high value assets including 15 patents and the increasingly successful Seratopical Revolution skin care product line, is very undervalued at current trading levels. The details are all well covered in the recent feature article below. AVRW is now set up to have a record sales and revenue growth year in 2024 based on all the positive groundwork that was laid in the past months.
$AVRW Feature: Media Grabbing Seratopical Revolution Skin Care Line, Personal Choice of Nicole Kidman for Years, Now Directly Recommended by LeadingLA Plastic Surgeon for Superior Anti-Aging Results
https://news.columbusnewsonline.com/story/478529/media-grabbing-seratopical-revolution-skin-care-line-personal-choice-of-nicole-kidman-for-years-now-directly-recommended-by-leadingla-plastic-surgeon-for-superior-antiaging-results-avrw.html?utm_source=dlvr.it&utm_medium=twitter
From this article:
– Proprietary Nutraceutical & Topical Delivery Systems for Wellness and Anti-Aging Beauty Product Lines.
– Company Currently Holds 15 Patents.
– Seratopical Revolution Skin Care Products are Promoted by the Company’s Global Brand Ambassador and Strategic Partner Nicole Kidman.
– LA-Based Facial Plastic Surgeon Dr. Michael Persky Directly Supporting Latest Seratopical DNA Complex Product.
– Media Exposure in Top-Tier Publications Including CNN Underscored, Page Six, PEOPLE Magazine, and More.
– Q3 Net Revenue Increased Sequentially from Q2 2023.
– Sales Expected to Increase Significantly During Q4 and Into 2024.
– Gross Margin Increased 80 Basis Points Quarter-to-Quarter with Further Expansion Expected in Q4.
– Upcoming Launch of New Beauty Product Releases &New Marketing Initiatives.
– Latest Sales Results Show Accelerating Strength via New Marketing Campaigns.
$RWGI Update- New Improved https://buff.ly/3Ok47FZ website is launched with new area to bring on Wholesale Customers. Make sure to subscribe for updates and product offers. #StockstoWatch #cannabisindustry #Growth #Acquisition #revenue #Success
$RWGI Update- New Improved https://t.co/7XLgtdMXHv website is launched with new area to bring on Wholesale Customers. Make sure to subscribe for updates and product offers. #StockstoWatch #cannabisindustry #Growth #Acquisition #revenue #Success pic.twitter.com/6XLkpfvmXo
— Rodedawg International Industries Inc (@RWGImerger) January 31, 2024
$RWGI News: Rodedawg Intl. Ind, Inc. (OTC: RWGI) Acquires and Initiates New California Cannabis Distributor License
COSTA MESA, CA , Jan. 24, 2024 (GLOBE NEWSWIRE) -- Rodedawg International Industries, Inc. (OTC: RWGI) proudly announces the Company, through our wholly owned subsidiary, Parabola Mgmt. LLC, has acquired a new California cannabis distributor license in Coachella, California. Chris Swartz, CEO, states “We are proud to inform our shareholders that since the completion of the acquisition of Parabola Mgmt., LLC we have already started the acquisition and expansion of our cannabis license portfolio. We are especially proud to make this announcement as this is a first quarter 2024 milestone that has happened within the timeline of the Company roadmap. As we had previously stated, the acquisition of Parabola Mgmt. LLC included options to purchase additional licenses, we have moved quickly to complete the first purchase and we will continue moving quickly toward expanding the revenues of the Company. We are confident that our strategically planned acquisitions and merger strategy for 2024 will increase 2024 revenues to meeting and potentially exceeding our stated goal of 7 million annually”.
Mr. Swartz concludes, This is one of the many regular updates our shareholders can expect as we complete our 2024 roadmap milestones during this 1st Quarter 2024 that will lead to the significant increases to revenue growth. Once again, we continue to thank our loyal shareholders for their ongoing support as we create Rodedawg to becoming an industry leader in the licensed cannabis market.”
About Rodedawg International Industries, Inc.
Rodedawg International Industries, Inc. (OTC: RWGI) is focused on providing management services, acquisitions and restructuring resources throughout the regulated California cannabis market. We are a trusted partner and asset to licensed cultivation, distributors, manufacturers, and retail dispensaries.
Please note the company Twitter address is https://twitter.com/RWGImerger for regular updates.
About Budding Horizon, LLC
Budding Horizon, LLC is a California Limited Liability Company with offices in Orange County, California. The company is focused to providing management services for the licensed cannabis industry and seeks to leverage its expertise in the real estate acquisitions to acquire and develop a portfolio of assets.
The company website is https://buddinghorizon.com/
About Brother Buds™
Brother Buds is a cannabis delivery service based in Costa Mesa, California. During the month of July 2023, the Rodedawg will operate Brother Buds under a non-storefront cannabis delivery license. The cannabis delivery service will focus on Los Angeles County, Orange County, and norther San Diego County in the demographic area of 23.86 million in 2019. The company is focused to providing management services for the licensed cannabis industry and seeks to leverage its expertise in the real estate acquisitions to acquire and develop a portfolio of assets.
The company website is https://BrotherBuds.com
Make sure to follow us at https://twitter.com/BrotherBudsOC
Safe Harbor Statement: In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that would cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward-looking statements.
SOURCE: Rodedawg International Industries, Inc.
$BDPT bids grew today...going to pop soon-MY TOP .000 PLAY.
$RWGI - "As a vertically integrated cannabis company, $RWGI is well positioned to grow with retail, wholesale, and manufacturing markets.”, CEO Chris Swartz
Source:
https://www.marijuanamoment.net/marijuana-will-gain-millions-of-consumers-over-alcohol-with-sales-hitting-37-billion-by-2027-investment-bank-projects/#:~:text=A%20multinational%20investment%20bank%20says,loses%20a%20couple%20million%20drinkers
$BDPT .0005 keep accumulating...LOW SS can run, NEWS pending
$BDPT .0005/6 low ss and news recently....AI technology for body weight/sculpture and health care line.
Added to my watch list. Thanks
ABQQ @ABIntlGroup
Currently, working with legal team and accountant expert also. Most probably get started soon and then the journey of “reduce shares” will involve time to time until the market price $4 which is meets the requirements of uplisting
6:30 pm · 18 Jan 2024
·
1,324
Views
I will penny.
Find is a good one Rocket $$
She blocks everyone. (Maybe to do with the devil). Try AXXA. Like to hear your spiel on that one.
I want to find a long term stock like sp*zi...the otc want another. I tried following you but im blocked lol
I want to find a long term stock like sp*zi...the otc want another. I tried following you but im blocked lol
HI CJ2...can you follow me on Twitter...I think somehow were blocke @StockRocket1
Also I want to align with you in a .000 or thereabouts long term play...
$VTXB .0005 Here is why--->
$VTXB .0005 should be on everyones radar-#bitcoin miner that issued dividends.🚀IMPORTANT: increase your chances winning on #OTC look for co.'s, though very rare, with NO CONVERTIBLE NOTES (#1 killer of OTC stocks moving on L2) $VTXB has 0 notes & very little dilution as of late. pic.twitter.com/4ogbQAn9jO
— stockrocket1 (@StockRocket1) December 24, 2023
Watchlist: $RSPI .0011 NEW🚀ALERT ADDED TO MY LIST BASED ON RECENT FILINGS/CHART/*BELOW.
Sr. VP Will Clodfelter: • 30+ International/Domestic Pharmaceutical Licensing!•Formerly at Eli Lilly & Amylin Pharmaceuticals • MD at PONTO Ventures that closed 3.5 Billion DEAL•RSPI many PATENTS
Please put on watch list. $BCNN .0011 very small OS float news just on on record revs.
$SMME: SmartMetric Technology Bringing a Fully Functional Fingerprint Scanner Inside Your Credit Card, Taking Credit Card Security to the Next Level
November 15, 2023
NEW YORK--(BUSINESS WIRE)-- SmartMetric, Inc. (OTC: SMME) the miniature nano fingerprint scanner built by SmartMetric to fit inside a standard credit and debit card takes credit card security to the next level.
Before using your pin or any other clumsy old credit and debit card security, cards with the SmartMetric nano fingerprint scanner inside provide a powerful first step in securing the card prior to it being used. The card holders’ fingerprint is matched with their fingerprint that is scanned by the nano internal scanner each time the card holder goes to use their card.
A small square fingerprint sensor sits on the surface of the card that is connected to a circuit board inside the card. On this circuit board are extremely small and very low-profile electronic components that allow the users fingerprint to be scanned and matched in less then a second. On a fingerprint match the cards contact chip and contactless RFID is unlocked allowing the card to then operate at any standard card reader and ATM.
Enrolling a fingerprint on the card for the first time is as simple as enrolling your fingerprint on a mobile phone. Touch the sensor up to four (4) times and your fingerprint is then forever embedded inside the cards encrypted memory. The memory for storing the fingerprint is firewalled and uses extremely strong encryption.
“We had to build a super thin and small device that fits inside a standard credit card having amongst a number of components, a MCU, Power Management System, Internal Memory along with other components. Not to mention a super thin rechargeable hybrid nano battery,” said SmartMetric’s President and CEO, Chaya Hendrick.
Well over a decade of research and development has gone into creating the new GEN4 SmartMetric biometric card according to SmartMetric.
The new GEN4 card is now in mass production. A small sample run of the assembled card was completed to test the cards latest operating system developed by SmartMetric. The software testing and the cards functioning has been successfully completed.
“We are excited about the future prospects for our 'patent protected' product after spending so many years of research and development,” said Chaya Hendrick.
Patents for the technology have been issued recently in the United States while other patents covering other parts of the world have been filed.
“These recently issued patents disallow others from making biometric credit cards that have a fingerprint sensor on the card according to SmartMetric.”
“A massive market for an incredible next generation credit card,” said SmartMetric’s President and CEO, Chaya Hendrick.
Over 300 million credit cards have been issued in the United States. Consumer research reveals that up to 70% of existing credit card holders are willing to pay for a biometric secured credit card.
“The SmartMetric biometric credit card has taken years to develop and its Gen4 product designed for credit card issuing banks, is now in production said SmartMetric.”
The SmartMetric biometric fingerprint activated credit card brings the power of biometric security to the regular credit and debit card. Using the cardholder's own fingerprint only the cardholder is able to use the card. Touching the cards sensor on the cards surface awakens the card to scan the user’s fingerprint in less than a second. The fingerprint is matched with the users pre-stored fingerprint that has been registered inside the cards internal cryptographically secured memory.
“Research has shown that up to 70% of existing credit card users are attracted to using a biometric credit card. However, for this to be achieved the card itself must be as easy and simple to use as a current credit card and must most definitely be able to be biometric secured and safe in all card reading situations,” said Chaya Hendrick.
SmartMetric is now in mass market production of its GEN4 advanced biometric credit card. The company is preparing to release its advanced biometric credit card to the global credit card issuing community.
The SmartMetric GEN4 Biometric Fingerprint Card has been developed to meet the specific demand of the credit card industry and credit card users for enhanced credit card security. The card has an in-the-card nano fingerprint scanner that is used to recognize the card holders fingerprint and in turn activate the card.
The SmartMetric biometric credit card is the only advanced biometric payments card product with an internal rechargeable battery that allows the card to be used in all card usage cases such as restaurants and ATM’s. Having its own power inside the card allows the SmartMetric biometric card to work prior to the card being inserted into a card reader.
The SmartMetric biometric fingerprint recognition technology built inside of the credit and debit card uses embedded biometric technology to positively recognize the card holder and then only after a positive fingerprint recognition, turn on the cards EMV contact and contactless payments chip.
According to an article published by Finder.com1 the number of credit card accounts open in the United States is 564,500,000. This is an all-time high for the United States.
The average American owns three credit cards. 83% of Americans own at least one credit card. 14% of Americans own at least 10 credit cards.
SmartMetric plans to sell its advanced biometric credit card to card issuing Banks for $50.00 a card. In turn Banks will decide whether or not to provide the card for free to its card users or offer it as a premium card to its top tier card users for a fee.
To view the SmartMetric Biometric Card please follow this link - Video of the SmartMetric Biometric Card. To view the company website: www.smartmetric.com
1 2023 Credit card debt and spending statistics in the US | finder.com
Safe Harbor Statement: Forward-Looking Statements in this press release, which are not historical facts, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Also such forward-looking statements are within the meaning of that term in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Our actual results, performance or achievements may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," "likely," "will," "would" and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by us and our management, are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, among others, if we are unable to access the capital necessary to fund current operations or implement our plans for growth; changes in the competitive environment in our industry and the markets where we operate; our ability to access the capital markets; and other risks discussed in the Company's filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K, which filings are available from the SEC. We caution you not to place undue reliance on any forward-looking statements, which are made as of the date of this press release. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. Investors and security holders are urged to carefully review and consider each of SmartMetric Inc. public filings with the SEC, including but not limited to, if applicable, Annual Reports on Form 10-K, proxy statements, Current Reports on Form 8-K and Quarterly Reports on Form 10-Q.
https://cts.businesswire.com/ct/CT?id=bwnews&sty=20231115029949r1&sid=acqr8&distro=nx&lang=en
View source version on businesswire.com: https://www.businesswire.com/news/home/20231115029949/en/
SmartMetric, Inc.
Chaya Hendrick
Tel: (702) 990-3687
Mobile: (305) 607-3910 (Pacific Time)
ceo@smartmetric.com
http://www.smartmetric.com
Source: SmartMetric, Inc.
$SITS: Southern ITS International, Inc. Subsidiary, Pure Oil & Gas, Inc., Reports on Oil Production Numbers and Announces a New 4-Well Drilling Project in Texas
Palm Desert, California, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Southern ITS International, Inc. (Pink Open Market: SITS) proudly announces a significant achievement for its subsidiary, Pure Oil & Gas, Inc., as it began sales of oil produced by one of its wells in Texas. Production in October yielded three loads of oil—510 barrels—which has been collected and sold to BML Inc.
This success sets the stage for Pure Oil & Gas, Inc.’s next venture – a four-well drilling project in Texas.
The first new well is scheduled to begin drilling in the first week of December 2023, with production anticipated to commence within four weeks of the start of drilling operations. Funding for this new project has been secured.
Jeremy Larsen, President of Pure Oil & Gas, Inc. stated, “We are thrilled to announce our successful entry into the Texas oil reserves and look forward to the promising opportunities that lie ahead with our upcoming four-well drilling project. Our strategic location in Texas provides us with a valuable resource base, and we are confident that our collaboration with ICS Energy will contribute to the efficiency and success of our drilling operations.”
Pure Oil & Gas, Inc. has partnered with ICS Energy, LLC, an experienced driller-operator with extensive expertise in the regional geological landscape. This collaboration aims to optimize operations and bolster Pure Oil & Gas's position in the energy sector.
About Pure Oil & Gas, Inc.
Pure Oil & Gas, Inc. focuses on leveraged oil and gas acquisitions as a key strategy for growth and establishing a strong position in the industry. Supported by its parent company, Southern ITS International, Inc., Pure Oil & Gas leverages financial flexibility provided by its parent to acquire leases, producing wells, oil services companies, and new oil industry technology.
About Southern ITS International, Inc.
Southern ITS International, Inc., through its subsidiary companies, currently has operations focused on a wide variety of fields, including oil and gas exploration and development, clothing, and e-commerce fulfillment. We intend to expand upon our current base of operational companies and to increase our ownership and/or control of a portfolio of highly successful businesses. As a holding company, Southern ITS International continues to be in the market to acquire a stake in various companies, both public and private, which will complement its current operations. Our mission includes establishing a robust Direct-to-Consumer (DTC) and Business-To-Business (B2B) network, harnessing the potential of e-commerce across an array of diverse sectors, including manufacturing, distribution, and product sales. We have put in place an experienced management team that is continuing to build a diverse portfolio, buying entire companies, or interests therein, involved in technology, oil and gas, manufacturing, real estate, and other sectors, which will then become operating subsidiaries of Southern ITS International.
Precautionary and Forward-Looking Statement
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may" "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude or risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of several factors, and other risks identified in the Company's disclosures or filings with the SEC or OTC Markets, Inc. You are further cautioned that penny stocks and stocks of smaller companies like Southern ITS International, Inc. are inherently volatile and risky, and that no investor should buy this stock unless they can afford the loss of their entire investment.
$IDVV.0016 NEWS JUST OUT....EXTINGUISHED ALL DEBT..ARTIFICIAL INTELLIGENTCE AI COMPANY...INCOMING MERGER
https://www.otcmarkets.com/stock/IDVV/news
https://twitter.com/StockRocket1/status/1729910381143880168
$IVDN (16 million float): Innovative Designs Inc. Receiving Orders From Numerous New Client Accounts for Top Performing Insultex House Wrap With Unmatched R-6 Insulation Value
PITTSBURGH, PA, Oct. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - Innovative Designs, Inc. (OTCQB: IVDN) is pleased to announce that in the company’s fiscal fourth quarter, we have gained over a dozen new client accounts for our patented, R-6 rated Insultex House Wrap®, with product being shipped out to meet rising demand. The new clients and other interested parties contacting us include some high market cap companies that are very important participants in the home building and remodeling industry. One reason for the accelerating interest in Insultex House Wrap® appears to be related to new building codes going into effect across the US which require higher insulation performance standards. Insultex House Wrap® meets or exceeds these standards where many competitive products do not.
Insultex House Wrap® can provide an unmatched R-6 rating because of our unique and patented vacuum cell structure design. No other product on the market today offers a vacuum cell structure. It has been proven that a vacuum is the best thermal insulation and Insultex® incorporates countless evacuated cells. Our newly updated website explains the scientific principles in detail along with graphic visual aids. Insultex® also provides a moisture barrier and other key benefits that make it simply the best insulation choice for all home builders and home remodelers in projects of any size.
The Insultex House Wrap ® website may be visited at http://www.insultexhousewrap.com. In response to the rising customer interest, the website now includes a new e-Commerce section where orders for the product may be placed directly online for orders of less than 5 rolls. All other orders are handled directly.
Innovative Designs, Inc. CEO Joseph Riccelli said, “Word is starting to spread about the availability of Insultex House Wrap® which is the only insulated house wrap product on the market today. As more home builders and home remodelers learn of this game-changing advancement, they are coming to us with new orders in growing numbers. Because we have been working diligently over the past several months to ramp up our order fulfillment capability, Innovative Designs is ready to handle increasing order levels at this time with plans underway for even further manufacturing capacity enhancement. We project this unparalleled product to gain substantially more market share going forward.”
About Innovative Designs, Inc.
Innovative Designs, Inc. manufactures the Insultex® House Wrap and Arctic Armor® Line, under the "i.d.i.gear" label featuring INSULTEX®. Patented INSULTEX® is the thinnest, lightest and warmest insulator in the market today. For more information, please visit http://www.idigear.com or http://www.insultexhousewrap.com.
Disclaimer
Certain statements in this press release constitute "forward-looking" statements as defined by federal law. Such statements are based on assumptions, but there is no assurance that actual outcomes will not be materially different as those implied. Any such statements are made in reliance on the "Safe Harbor" protections provided under the Private Securities Reform Act of 1995 and are subject to various factors, including the risks and matters discussed in the Company's SEC filings available at http://www.sec.gov.
CONTACT:
Joseph Riccelli, CEO
412-799-0350
joer@idigear.com
$NICH NEWS JUST OUT.. VERY LOW FLOAT JUST LEAVING TRIPS. $$$$ THIS ONE WILL RUN...TOOK A STARTER. $SONG $TMSH $CLNV $INCC $YMCR $CMGR $BIEI $SANP $HMBL $SANP $GTLL $OPTI
$LLLI News: Lamperd Less Lethal Receives Order and Full Payment for Special Munitions Rounds from New International Customer
SARNIA, ON / May 31, 2023 / Lamperd Less Lethal, Inc. (OTC PINK:LLLI), an innovation leader and manufacturer of advanced security solutions for law enforcement, military and security agencies worldwide, has received an important police services order with full payment from a new international customer. This order is for a special type of less lethal munition which Lamperd has carefully developed in conjunction with The University of Western Ontario.
One of the reasons this customer selected Lamperd Less Lethal was the quick delivery time which we can provide. Because Lamperd performs all manufacturing in-house and also has well established local raw materials suppliers, we are able to fulfill orders in much shorter time frames than our competitors who are currently taking many months or even over a year to deliver. Lamperd can manufacture and fulfill most orders in a matter of a few weeks.
Lamperd offers a wide range of less lethal munitions for 37mm, 40 mm, 20 gauge and 12 gauge weapons so officers can have the right tool for every job. These options include our proven WASP & SOC Impact rounds as well as Muzzle Blast Pepper, including Aerial Burst, Green Sticky Gel, Door Breacher and lower capacity Training Rounds.
Lamperd’s OC Aerial Burst munitions can travel 100+ ft and cover an area of 200 sq.ft for more effective and safer riot control. These rounds drop no dangerous debris, only a powerful but harmless OC compound to disburse unruly crowds. Lamperd offers Aerial Burst options for multiple types of launching systems including 20 gauge and 12 gauge police shotguns that are in widespread use around the world.
Lamperd Less Lethal also offers a full line of Humane Animal Control Products to protect police, animal control and other officers from aggressive animals without having to resort to deadly force. Too many pets and other animals are needless killed each year but Lamperd has the solution with less lethal munitions that can scare off an aggressive dog or other animal without causing any harm. Every police department and animal control agency should have these options in use.
Lamperd Less Lethal has be best safety record in the global less lethal industry. For over 50 years there have been zero deaths and zero serious injuries resulting from the use of any Lamperd products.
See the full Lamperd Less Lethal product line and training services available at http://www.lamperdlesslethal.com.
About Lamperd Less Lethal:
Lamperd Less Lethal, Inc. (LLLI) is a developer, manufacturer and international sales company for advanced less lethal weapons, ammunition and other security products marketed to police, correctional, military and private security forces. The company manufactures and sells over 300 different products including small & large caliber projectile guns, flash-bang devices, pepper spray devices, 12 Gauge, 37mm & 40mm launching systems and a variety of different riot shields. Lamperd also offers advisory services and hands-on training classes run by highly accredited instructors. For more information visit: http://www.lamperdlesslethal.com
This press release contains forward-looking statements relating to Lamperd Less Lethal, Inc. Lamperd Less Lethal, Inc. undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results. Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
Contact: Lamperd Less Lethal, Inc.
Barry Lamperd, President & CEO
(519) 344-4445
Email: info@lamperdlesslethal.com or sales@lamperdlesslethal.com
Company Website: http://www.lamperdlesslethal.com
Lamperd Less Lethal on Facebook: https://www.facebook.com/lamperdlesslethal
Lamperd Less Lethal on Twitter: https://www.twitter.com/LLLI_LessLethal
Barry Lamperd on Twitter: https://www.twitter.com/lamperd_llli
SOURCE: https://ih.advfn.com/stock-market/USOTC/lamperd-less-lethal-pk-LLLI/stock-news/91204709/current-report-filing-8-k
$LLLI News: Lamperd Less Lethal is Prepared to Deliver Advanced Riot Shields in a Range of Sizes and Types with Quickest Order Fulfillment Thanks to In-House Production
Interlocking Riot Shields and Specialized Versions Available for Every Application
In-House Production and Local Material Sources for Quick Delivery Times
Long Established Reputation for the Highest Quality and Versatile Designs
SARNIA, ON / ACCESSWIRE / May 2, 2023 / Lamperd Less Lethal, Inc. (OTC PINK:LLLI), an innovation leader and manufacturer of advanced security solutions for law enforcement, military and security agencies worldwide, is fully prepared to meet the rising need for riot shields in the United States, Canada and other countries around the world. With protests, demonstrations, riots and other public order crisis at an escalating level today, Lamperd is ready with the most advanced, extensive and versatile line of riot shields for every situation. Lamperd riot shields are currently serving all over the globe with police, military and correctional facility customers.
Lamperd Less Lethal can deliver completed orders for riot shields on a very timely basis as we perform all manufacturing in-house at our fully equipped and well staffed plant in Sarnia, Ontario with no outsourcing needed. Lamperd also has established very dependable local sources for all raw materials needed. Therefore, we can offer the quickest order fulfillment of any riot shield provider, generally in a matter of weeks as opposed to many months or even over a year, as is the case with other suppliers at this time. Lamperd manufacturers the entire shield, including our own handles, with the option of custom handles for specialized requirements.
The Lamperd Less Lethal riot shield line offers many different types and sizes as can be reviewed on our company website here: https://lamperdlesslethal.com/product-category/police-riot-shields-protective-gear/. Sizes are available from 24 inch (610mm) up to 71 inch (1800mm) with 4.5mm or 3mm thickness and optional gun ports for less lethal weapons. Our advanced interlocking feature can allow multiple Lamperd riot shields to be quicky linked together to form a strong, interlocking barrier. Lamperd Interlocking Riot Shields are currently being used by many police agencies throughout the United States. Curved, Round and Non-Interlocking types are also available for different applications. Whatever law enforcement needs, Lamperd is able to deliver it, in the highest manufacturing quality and any size quantity, large or small.
The Lamperd Capture Shield is available in sizes up to 6 foot tall (to our knowledge, the longest on the market). Our Capture Shield allows corrections officers to pin an unruly prisoner against a wall to safely regain control. Strong, clear Lexan material is used for lightweight ease of handling and maneuverability. The Lamperd Capture Shield is currently in use at correctional facilities throughout Canada. For more detailed information, photos and a demonstration video visit the Lamperd website here: https://lamperdlesslethal.com/product/lamperd-capture-shield/
Lamperd Extraction Shields are another available option, ideally sized and shaped to help prevent broken ribs and other common injuries or bodily fluid contamination while transferring persons to and from police cars, ambulances or other tight spaces. The Lamperd Extraction Shield is made of strong, clear polycarbonate to allow clear vision and is equipped with padded handles. Especially important is the arm handle which will flexibly move in and out in response to pressure to help prevent broken ribs as can happen with other rigid handle shields. See and learn more on the Lamperd website here: https://lamperdlesslethal.com/product/extraction-shield/.
Training models of the Lamperd Capture Shields and our Extraction Shields are also available. These special training versions are designed to allow officers to more safely practice their techniques with a greater degree of safety.
Barry Lamperd, CEO of Lamperd Less Lethal, commented, "We are very proud of our long track record for supplying vital riot shields in many different types and sizes to law enforcement and military units all over the world. Our design teams have worked in conjunction with the University of Western Ontario and other highly accredited institutions as well as with feedback from the officers we serve to develop and produce riot shields with the exact features that are needed to make them the most effective and useful in real world functions. At this time when riot shield demand is rising to a peak and availability from other sources is often limited or facing extended order fulfillment times, we want to make sure that everyone knows Lampred Less Lethal is ready and able to meet all riot shield needs with the quickest delivery times in the industry. We also invite all law enforcement and other government agency representatives to visit our facility to see our manufacturing operation and to do hands-on evaluation of our products at any time."
About Lamperd Less Lethal:
Lamperd Less Lethal, Inc. (LLLI) is a developer, manufacturer and international sales company for advanced less lethal weapons, ammunition and other security products marketed to police, correctional, military and private security forces. The company manufactures and sells over 300 different products including small & large caliber projectile guns, flash-bang devices, pepper spray devices, 12 Gauge, 37mm & 40mm launching systems and a variety of different riot shields. Lamperd also offers advisory services and hands-on training classes run by highly accredited instructors.
For more information visit: http://www.lamperdlesslethal.com.
This press release contains forward-looking statements relating to Lamperd Less Lethal, Inc. Lamperd Less Lethal, Inc. undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results. Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
Contact: Lamperd Less Lethal, Inc.
Barry Lamperd, President & CEO
(519) 344-4445
Email: info@lamperdlesslethal.com or sales@lamperdlesslethal.com
Company Website: http://www.lamperdlesslethal.com
Lamperd Less Lethal on Facebook: https://www.facebook.com/lamperdlesslethal
Lamperd Less Lethal on Twitter: https://www.twitter.com/LLLI_LessLethal
Barry Lamperd on Twitter: https://www.twitter.com/lamperd_llli
SOURCE: Lamperd Less Lethal, Inc.
View source version on accesswire.com:
https://www.accesswire.com/752283/Lamperd-Less-Lethal-is-Prepared-to-Deliver-Advanced-Riot-Shields-in-a-Range-of-Sizes-and-Types-with-Quickest-Order-Fulfillment-Thanks-to-In-House-Production
$GMPR has key marketing outlets like the Sedanos chain for distributing its gourmet food items .
Gourmet Provisions International @GourmetProvInt
Our first delivery has been shipped and received to UNFI, the distributor for the 40
@Sedanos
locations & 1000’s of other grocery stores. Our sales team will be in Florida in early January to work with Sedano’s management to set up & demo the products in all 40 locations $GMPR
Our first delivery has been shipped and received to UNFI, the distributor for the 40 @Sedanos locations & 1000’s of other grocery stores. Our sales team will be in Florida in early January to work with Sedano’s management to set up & demo the products in all 40 locations $GMPR pic.twitter.com/zD3KnbgKJt
— Unique Global Innovative Solutions Corp (@Unique_Global_) December 22, 2022
$LLLI Lamperd Less Lethal is now offering advanced police training courses worldwide for the proper use of less lethal security products to control crisis situations effectively and safely.
$LLLI Lamperd Less Lethal Now Offers Highly Accredited Security Products Training Courses on a Worldwide Basis SARNIA, ON / December 7, 2022 / (OTC PINK: LLLI) #LessLethal #PoliceTraining #MilitaryTraining #RiotControl #EmergencyResponse #International https://t.co/jWeMfQuLHW pic.twitter.com/oEOyT6UOrx
— LamperdLessLethal (@LLLI_LessLethal) December 7, 2022
$CDSG News: China Dongsheng International Appoints Craig Alford, CEO
Las Vegas, NV. , Jan. 24, 2023 (GLOBE NEWSWIRE) -- China Dongsheng International Inc., (OTC Markets: CDSG) (the "Company" or "CDSG") is pleased to announce the appointment of Mr. Craig Alford as a Chief Executive Officer.
Harp Sangha, President of CDSG states, "We are delighted that Mr. Alford will be joining the CDSG management team and providing his invaluable experience and leadership. Upon his appointment, Caren Currier will become the Chief Financial Officer of the firm."
North America's capacity for battery cell production will likely grow more than tenfold in the coming five years and there is a deficiency of production.
Consumer demand and government policies have been vital driving forces for the current rapid expansion of the battery metal sector. In October of 2022, the U.S. announced $2.8 billion in grants to boost U.S. production of electric vehicle batteries and the minerals used to build them. And now four of the world's five largest battery makers, CATL, Panasonic, SK and LG Energy Solutions have declared plans for production within the US, Mexico, and Canada.
About Craig Alford
Mr. Craig Alford holds both an Honors Bachelor of Science and a Master of Science in Geology. He is a registered Professional Geoscientist and is a Qualified Person, as defined in National Instrument 43-101. Mr. Alford's experience began with Falconbridge Copper in the early 1980's and has since included leadership positions worldwide with independent, junior and senior mining companies including, Teck Mining, Zijin Mining Group and China Railway Resources.
Mr. Alford has designed and provided management for projects throughout North and South America, SE Asia, China, Central Asia, Russia, Australia and Africa. Craig has managed projects within a broad spectrum of mineralized and political environments, helped raise millions of dollars in capital for exploration projects, has negotiated with several Heads of State and assisted the World Bank and the China-Africa Development Fund in tax policy, planning, and investment risk.
He has been responsible for budgeting and the expenditure of hundreds of millions of dollars and developed economic analysis for large M & A transactions. Mr. Alford's tenure as Deputy General Manager with the Zijin Mining Group resulted in large investments in Pretium Resources, Kyrgyzstan's Taldybulak Gold Mine, Norton Gold in Australia, Barrick Gold's Porgera mine and Ivanhoe Mines' Kamoa Copper Project. During this crucial time for the battery metal sector, Mr. Alford has been involved in a number of base metal and lithium exploration projects key to the industry.
About the company: China Dongsheng International Inc. (OTC Markets: CDSG) is an emerging company based in Nevada. The company's principal activity is advancing our Lithium project adjacent to the TLC project in Nevada as well as acquiring and developing opportunities in the natural resource sector and complimentary technologies.
For further information please visit www.cdsgholdings.co. or (702) 595-2247
Forward-Looking Statements:
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors, or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company's business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company's periodic filings with the Security and Exchange Commission.
$CDSG China Dongsheng International, Inc. intends to acquire public and private companies that are engaged in the technology, natural resource, and various other sectors. Currently CDSG is engaged in lithium exploration and mining projects to support the emerging electric vehicle industry.
https://lnkd.in/gguQtQub
$VRVR News: Virtual Interactive Technologies Corp. Launches All New, State of the Art Website to Showcase its Category-First Metaverse and Other Gaming Experiences
January 3, 2023 (PR Newswire)
New Marketing and IR Firm Hired to Assist Investors
Virtual Interactive Technologies Corp., (OTC: VRVR) ("VRVR" or the "Company"), an American multi-platform video gaming developer and publisher, is pleased to announce the launch of a new, state of the art company website which can be accessed at: http://www.vrvrcorp.com.
We invite investors and gamers to visit and explore our new website to learn about Virtual Interactive Technologies, its gaming products and the exciting vision we have for the future. This vision will include advancements in our unique, next-generation metaverse gaming with experiential immersion experiences for leading mobile and web platforms.
VRVR continues to build on its successful proprietary game catalog that features Duane Lee "Dog" Chapman, of the "Dog The Bounty Hunter" fame, Carmageddon Max Damage, Carmageddon Crashers, Interplanetary: Enhanced Edition, Catch & Release, and Worbital.
Additionally, VRVR has hired a new marketing firm, Dynamic Growth Media, LLC. that will handle Social Media, Marketing and Investor Relations. The mission for Dynamic Growth Media, LLC. will be to bring higher market awareness, a better understanding of the company and its developing product line.
About Virtual Interactive Technologies Corp.
Virtual Interactive Technologies Corp (OTC: VRVR) or ("the Company") is a next-generation game and metaverse developer publisher that creates experiential immersion experiences by harnessing the latest technologies, including Blockchain and digital assets. The Company's newly launched brand, Extrosive, is building a metaverse that replaces traditional boring financial experiences with a new paradigm, "global Prosperity space" (gPs). This new asset class dynamically augments global and local realities and builds communities of aligned financial values, virtuous economies, and a trusted network. The result would be a metaverse game for the glamorous world of Wall Street, High-Speed trading involving community building, quantified self, and NFTs - a pure adrenaline rush! In addition, the Company continues to build on its successful catalog that includes Carmageddon Max Damage, Carmageddon Crashers, Interplanetary: Enhanced Edition, Catch & Release, and Worbital. The Company also entered into a joint development partnership with Duane Lee "Dog" Chapman, of the "Dog The Bounty Hunter" fame, to develop and promote multiple games across several platforms.
For Additional Information:
Investor Relations: Call (303) 228-7120 or Email: info@vrvrcorp.com
Safe Harbor Statement / Forward-Looking Statements
This press release contains statements that constitute forward-looking statements. These statements appear in a number of places in this press release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; and (iii) growth strategy and operating strategy. The words "may", "would", "will", "expect", "estimate", "can", "believe", "potential", and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is included in the Company's filings on sec.gov.
https://c212.net/c/img/favicon.png?sn=LA74784&sd=2023-01-03
View original content to download multimedia:https://www.prnewswire.com/news-releases/virtual-interactive-technologies-corp-launches-all-new-state-of-the-art-website-to-showcase-its-category-first-metaverse-and-other-gaming-experiences-301711135.html
SOURCE Virtual Interactive Technologies
$GTVH has a new video update out that covers the multiple and simultaneous high value ventures coming into play for the company at this time...
$GTVH CEO, Steffan Dalsgaard, provides corporate update
Click here:
$GTVH CEO, Steffan Dalsgaard, provides corporate update.https://t.co/f1WXSMK8Xf
— Golden Triangle Ventures, Inc. (@GTV_Inc) October 13, 2022
ClickStream Corp. (OTC PINK: CLIS) subsidiary Rebel Blockchain, Inc., aka Nifter™, is ensuring the carbon footprint of their NFT platform’s global rollout is as minimal as possible and in line with Nifter™ evolving ESG strategy.
As the computational needs of the Rebel Blockchain will significantly increase as Nifter™ rolls out to a global audience, the Ethereum V2 merge will not only lower electrical costs but will also enable Nifter™ to lower its global impact while developing a plan for 100% carbon-neutral operations.
https://finance.yahoo.com/news/nifter-embraces-ethereum-v2-sustainability-132700078.html
Followers
|
58
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1094
|
Created
|
09/07/14
|
Type
|
Free
|
Moderator pennypirate | |||
Assistants Carjockey2 pastrychf05 Sandera |
Always on the hunt for the next big
runner or just $$ making trades.
All are welcomed to post tickers..
Posts Today
|
0
|
Posts (Total)
|
1094
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |